RESEARCH PAPER
Increase in glycaemia stimulates reactive oxygen species (ROS) production by polymorphonuclear neutrophils in type 2 diabetic patients
1
Department of Internal Medicine and Diabetology, University of Medical Sciences, Poznan, Poland
2
Department of Cardiology and Intensive Therapy, University of Medical Sciences, Poznan, Poland
Corresponding author
Dorota Pisarczyk-Wiza
Department of Internal Medicine and Diabetology, University of Medical Sciences, Raszeja Hospital, Mickiewicza 2, 60-834 Poznan, Poland; tel.: +4861 844579; fax: +48618474579.
Department of Internal Medicine and Diabetology, University of Medical Sciences, Raszeja Hospital, Mickiewicza 2, 60-834 Poznan, Poland; tel.: +4861 844579; fax: +48618474579.
J Pre Clin Clin Res. 2011;5(1):22-27
KEYWORDS
ABSTRACT
Polymorphonuclear neutrophils (PMNs), oxidative stress and hyperglycaemia play important roles in the development of
micro- and macroangiopathy in diabetes. The aim of this study was to evaluate the infl uence of a meal and the increment
of postprandial glycaemia on reactive oxygen species production by PMNs in type 2 diabetic patients.
The study was performed on 25 patients – 18 women and 7 men, aged 61.7+10.5 years, diagnosed with type 2 diabetes for
16.0+7.5 years, and in 20 healthy control subjects. PMNs were isolated from the blood by single-step gradient centrifugation.
The superoxide anion (O2
-) production by PMNs was measured spectrophotometrically by cytochrome C reduction, and the
hydrogen peroxide (H2O2) level was measured spectrophotometrically by phenyl red oxidation. A signifi cant correlation was
observed between an increase in glycaemia and O2
- production (r=0.52, p<0.05) and in H2O2 production by PMNs (r=0.43,
p<0.05). The results obtained suggest that in obese type 2 diabetic patients it is the increment of postprandial glycaemia,
and not directly the meal itself, that stimulates reactive oxygen species production by PMNs. This might play an important
role in the development of late vascular complications and thus have clinical implications.
REFERENCES (37)
1.
United Kingdom Prospective Diabetes Study Group (UKPDS): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;12:837-53.
2.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetespatients. Diabetes Care 2000;23(Suppl 2):B21-B29.
3.
Th e Diabetes Control and Complications Trials (DCCT) Research Group: Th e eff ect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329(14):977-86.
4.
Hanefeld M, Fisher S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Zeigelasch HJ, Lindner J. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study 11-year follow-up. Diabetologia 1996;39(12):1577-1583.
5.
Danahue R, Abbott R, Reed D. Post challenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36(6):689-692.
6.
Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, Eschwege E. High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study and the Helsinki Policemen Study. Diabetes Care 1998;21(3):360 367.
7.
Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary heart disease risk and impaired glucose tolerance: the Whitehall Study. Lancet 1980;1(8183):1373-1376.
8.
Ceriello A. Th e emerging role of postprandial hyperglycemic spikes in the pathogenesis of diabetic complications. Diab Med 1998;15:188- 193.
9.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
10.
Ishii H, Koya D, King GL. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998;76:1-31.
11.
Schmid MI, Duncan BB, Sharett AR. Markers of infl ammation and prediction of diabetes mellitus in adults (Atherosclerosis risk in communities study): a cohort study. Lancet 1999;353:1649-1652.
12.
Zozulińska D, Majchrzak A, Markiewicz S, Wierusz-Wysocka B. Selected markers of infl ammation in diabetic patients. Diabetes Res 1996;3:33-39.
13.
Zozulińska D, Wierusz-Wysocka B. Hyperglycemia and infl ammation are culprits of late complications. Arch Med Sci 2005;1:115-118.
14.
Halliwell B. Th e role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993;23(Suppl1):118-126.
15.
Freeman BA, Crapo JD. Biology of disease: Free radicals and tissue injury. Lab Invest 1982; 47:412-46.
16.
Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996;33:257-267.
17.
Baynes JW, Th orpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48(1):1-9.
18.
Takahashi T, Hato F, Yamane T, Inaba M, Okuno Y, Nishizawa Y, Kitagawa S. Increased spontaneus adherence of neutrophils from type 2 diabetic patients with overt proteinuria. Diabetes Care 2000;23:417- 418.
19.
Wierusz-Wysocka B, Wysocki H, Byks H, Zozulińska D, Wykrętowicz A, Kaźmierczak M. Metabolic control and free radical activity in diabetic patients. Diabetes Res Clin Pract 1995;27(3):193-197.
20.
Wierusz-Wysocka B, Wysocki H, Wykrętowicz A, Klimas R. Th e infl uence of increasing glucose concentration on selected functions of polymorphonuclear neutophils. Acta Diabetol Lat 1988;25:283-288.
21.
Boyum A. Isolation of lymphocytes, granulocytes and macrophages. Scand J Immunol 1976;Suppl 5:9-15.
22.
Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. Th e production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973;52(3):741-744.
23.
Pick E. Microassays for superoxide and hydrogen peroxide production and nitroblue tetrazolium reduction using an enzyme immunoassay microplate reader. Methods Enzymol 1986;132:407-421.
24.
Caimi G, Canino B, Montana M, Ventimigilia G, Catania A, Lo Presti R. Polymorphonuclear leukocyte membrane fl uidity and cytosolic Ca2+ concentration in diabetes mellitus. Acta Diabetol 1998;35:158-160.
25.
Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leukocyte functions in diabetic patients. Diabet Med 1997;14(1):29-34.
26.
Marhoff er W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992;15:256-260.
27.
Omori K, Ohira T, Uchida Y, Ayilavarapu S, Batista EL Jr, Yagi M, Iwata T, Liu H, Hasturk H, Kantarci A, Van Dyke TE. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol 2008;84:292-301.
28.
Morel F. Molecular aspects of chronic granulomatous disease – ‘the NADPH oxidase complex’. Bull Acad Natl Med 2007;191:377-390.
29.
Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000;85:2970-2973.
30.
Wierusz-Wysocka B, Wysocki H, Siekierka H, Wykrętowicz A, Szepanik A, Klimas R. Th e evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol 1987;42:519-523.
31.
Zozulińska D, Wierusz Wysocka B, Wysocki H, Majchrzak A, Wykrętowicz A. Th e infl uence of IDDM duration on superoxide anions and hydrogen peroxide production by polymorphonuclear neutrophils. Diabetes Res Clin Pract 1996;33:139-144.
32.
Zozulińska D, Majchrzak A, Markiewicz S, Wierusz-Wysocka B. Selected markers of infl ammatory in diabetic patients. Diabetes Res 1996;31:33-39.
33.
Matsuba KT, Van Eeden SF, Saito Y, Okazawa M, Klut ME, Hayashi S, Hogg JC. Functional changes in aging polymorphonuclear leukocytes. Circulation 1998;97:91-98.
34.
Wierusz-Wysocka B, Wykrętowicz A, Byks H, Sadurska K, Wysocki H. Polymorphonuclear neutrophils adherence, superoxide anion production (O2-) and HbA1 level in diabetic patients. Diabetes Res Clin Pract 1993;21:109-114.
35.
Ceriello A, Bartolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Felletto F, Catone B, Taboga C. Meal induced oxidative stress and low-density lipoprotein (LDL) oxidation in diabetes: the possible role of hyperglycemia. Metabolism 1999;48:1503-1508.
36.
Mohanty P, Ghanim H, Hamouda W, Aljada A, Garg R, Dandona P. Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. Am J Clin Nutr 2002;5:767-772.
37.
Brownlee M. Th e pathobiology of diabetic complications. Unifying Mechanism Glycation and diabetic complications. Diabetes 2005;54:1615- 1625.
Share
RELATED ARTICLE
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
